Fabian Stutz – CEO, Pharmabotix
Fabien Stutz, Co-Founder and CEO of Pharmabotix, leads a new wave of pharma-tech entrepreneurs combining engineering expertise with cutting-edge automation. He has helped grow the Swiss-based company into a globally…
Interpharma is the association of research-based pharmaceutical companies in Switzerland. It was founded in 1933 in Basel, Switzerland. Member firms are Novartis, Roche, Merck Serono, Actelion, Amgen Switzerland AG, Bayer Schering Pharma Schweiz, Cilag Switzerland, Vifor Pharma. In 2010, the Interpharma members spent 25 billion Swiss Francs on research an development which makes up 21 percent of their total sales in pharmaceuticals.
Interpharma is committed to creating conditions conducive to innovation in both Switzerland and abroad so as to promote pharmaceutical research, development and production. It supports all efforts to create a social, economic and political environment that strengthens Switzerland as a center of pharmaceutical research and production. Therefore, the association is an active partner in national health policy and fosters dialogue through its analyses, studies and other publications and events. Interpharma promotes a greater public understanding of new technologies and methods used in biomedical research and fosters the rigorous protection of intellectual property as an essential precondition for successful pharmaceutical research at the global and national level. It wants to help giving patients access to the latest medical advances as well as to safeguard and promote the development of professional and ethical standards in the research, development and marketing of pharmaceuticals.
Contact
Interpharma, Petersgraben 35
Fabien Stutz, Co-Founder and CEO of Pharmabotix, leads a new wave of pharma-tech entrepreneurs combining engineering expertise with cutting-edge automation. He has helped grow the Swiss-based company into a globally…
From her beginnings as an operating room nurse to her current role as Head of Varian EMEA, Virve Sarja has shaped a career grounded in purpose and driven by innovation.…
Marie Leblanc brings a distinctive combination of scientific rigor and commercial acumen to her role as Executive Vice President of Life Sciences at Biosynth, drawing from an 18-year tenure at…
Stephan Fritschi, recently appointed CEO at CARBOGEN AMCIS, brings nearly three decades of institutional knowledge to his new position. With 29 years of experience within the organisation, he has witnessed…
Dr. Roch Ogier, CEO of OM Pharma, brings a strong background spanning clinical medicine, neuroscience research, and leadership roles at Sanofi-Aventis, Vifor Pharma, and Novartis. Over the past eighteen months,…
Ryad Dahmani is a leading figure in healthcare technology, driving innovation in pharmaceutical cold chain logistics and assistive healthcare solutions. As the founder of ColdChain Vision and Body Health Technologies,…
As kidney disease places mounting pressure on global healthcare systems, innovation in dialysis becomes all the more critical, especially for patients receiving therapy at home. Enter Vivatum: a Swiss-Swedish medtech…
FarmaMondo’s evolution over the past eight years is a compelling case study in what it takes to bring life-saving innovation to the world’s most overlooked patients, not through philanthropy but…
Jorge Santos da Silva is the CEO and Co-founder of MoonLake Immunotherapeutics, a Swiss biotech company known for its bold approach to drug development. With a background in neuroscience, a…
Dr. Olivier Michielin serves as Head of Oncology at Geneva University Hospital (HUG) and Head of the Division of Precision Oncology, whilst maintaining his professorship at the University of Geneva…
Pharmaceutical manufacturing is evolving into a strategic pillar of competitiveness, shaped by modular design, digital integration, and a growing focus on long-term efficiency. Bilfinger, through its Technology segment, is playing…
Whether in the corridors of the FDA or the fast-evolving frameworks of ANVISA in Brazil, regulators around the world are undergoing a quiet revolution. While mature markets like the US…
See our Cookie Privacy Policy Here
